




Giảm đau và kháng viêm hiệu quả



Tài liệu tham khảo:

1. Tờ hướng dẫn sử dụng của Mobic
2. C. Hawkey et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. *British Journal of Rheumatology* 1998;37:937-945.
3. J. Dequeker et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX-2) inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. *British Journal of Rheumatology* 1998;37:946-951.
4. David Yocum et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis. *Arch Intern Med.* 2000;160:2947-2954.
5. M. Dougados et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. *Rheumatology* 1999;38:235-244.
6. Daniel E. Furst et al. Dose Response and Safety Study of Meloxicam Up to 22.5 mg Daily in Rheumatoid Arthritis: A 12 Week Multicenter, Double Blind, Dose Response Study versus Placebo and Diclofenac. *The Journal of Rheumatology* 2002; 29:3.
7. M. Distel et al. Safety of meloxicam: a global analysis trials. *British Journal of Rheumatology* 1996;35(suppl. I):68-77.
8. Gurkirpal Singh et al. Risk of Serious Upper Gastrointestinal and Cardiovascular Thromboembolic Complications with Meloxicam. *The American journal of medicine*, volume 117, July 15, 2004.
9. Deborah Layton et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. *Rheumatology* 2003;42:1354-1364, doi:10.1093.